Latest News and Press Releases
Want to stay updated on the latest news?
-
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel)
-
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
-
Autolus Therapeutics announces participation in upcoming conferences
-
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
-
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
-
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
-
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
-
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
-
Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALLComplete responses observed in patients with CD19 negative disease No antigen negative relapse seen in...
-
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US...